LIM-class homeobox gene Lim1, a novel oncogene in human renal cell carcinoma

Oncogene

Volumn 30, Issue 15, 2011, Pages 1753-1763

  Dormoy, V ^a   Beraud C ^a   Lindner, V ^b   Thomas, L ^a   Coquard, C ^a   Barthelmebs, M ^a   Jacqmin, D ^c   Lang, H ^c   Massfelder, T ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b CENTRE HOSPITALIER DE MULHOUSE   (France)

^c HÔPITAL CIVIL   (France)

Author keywords

developmental LIM class homeobox gene Lim1; growth; migration; renal cell carcinoma; VHL tumor suppressor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TENASCIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTION; CELL PROLIFERATION; CLINICAL ARTICLE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HOMEOBOX; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LIM1 GENE; MALE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE;

ANIMALS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; GENE SILENCING; HOMEODOMAIN PROTEINS; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ERINACEIDAE; MUS MUSCULUS;

EID: 79954610144     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.557     Document Type: Article

References (38)

1. Agouni A, Sourbier C, Danilin S, Rothhut S, Lindner V, Jacqmin D et al. (2007). Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3 K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B. Carcinogenesis 28: 1893-1901. (Pubitemid 47500600)
2. Arsanious A, Bjarnason GA, Yousef GM. (2009). From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer 8: 20.
3. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, De Bruine AP. (2010). VHL and HIF signalling in renal cell carcinogenesis. J Pathol 221: 125-138.
4. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W et al. (2007). Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524-2533. (Pubitemid 47582744)
5. Carroll VA, Ashcroft M. (2006). Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66: 6264-6270.
6. Chen J, Chen Z, Chen M, Li D, Li Z, Xiong Y et al. (2009). Role of fibrillar Tenascin-C in metastatic pancreatic cancer. Int J Oncol 34: 1029-1036.
7. Clark PE. (2007). Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol 17: 331-336. (Pubitemid 47344620)
8. Dormoy V, Danilin S, Lindner V, Thomas L, Rothhut S, Coquard C et al. (2009). The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. Mol Cancer 8: 123.
9. Escudier B, Cosaert J, Jethwa S. (2008). Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics 2: 517-530.
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M et al. (2009). Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318.
11. Friedrich CA. (1999). Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer 86: 2478-2482. (Pubitemid 30007530)
12. Hall A. (2009). The cytoskeleton and cancer. Cancer Metastasis Rev 28: 5-14.
13. Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E et al. (2008). Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 68: 81-88. (Pubitemid 351380108)
14. Hueber PA, Iglesias D, Chu LL, Eccles M, Goodyer P. (2008). In vivo validation of PAX2 as a target for renal cancer therapy. Cancer Lett 265: 148-155.
15. Hueber PA, Waters P, Clark P, Eccles M, Goodyer P. (2006). PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int 69: 1139-1145.
16. Imao T, Egawa M, Takashima H, Koshida K, Namiki M. (2004). Inverse correlation of microvessel density with metastasis and prognosis in renal cell carcinoma. Int J Urol 11: 948-953. (Pubitemid 39577188)
17. Kaelin Jr WG. (2007). The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13: 680s-684s.
18. Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, Majid S et al. (2009). Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 69: 8603-8610.
19. Kobayashi A, Kwan KM, Carroll TJ, McMahon AP, Mendelsohn CL, Behringer RR. (2005). Distinct and sequential tissue-specific activities of the LIM-class homeobox gene Lim1 for tubular morphogenesis during kidney development. Development 132: 2809-2823. (Pubitemid 40932870)
20. MacLennan GT, Bostwick DG. (1995). Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 46: 27-30.
21. Massfelder T, Lang H, Schordan E, Lindner V, Rothhut S, Welsch S et al. (2004). Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res 64: 180-188. (Pubitemid 38114096)
22. Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J et al. (2009). Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 101: 327-334.
23. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S et al. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
24. Nativ O, Sabo E, Reiss A, Wald M, Madjar S, Moskovitz B. (1998). Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology 51: 693-696. (Pubitemid 28261919)
25. Nogueira M, Kim HL. (2008). Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol 26: 113-124. (Pubitemid 351288566)
26. Ohno Y, Izumi M, Yoshioka K, Ohori M, Yonou H, Tachibana M. (2008). Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma. Oncol Rep 20: 511-516.
27. Reidy KJ, Rosenblum ND. (2009). Cell and molecular biology of kidney development. Semin Nephrol 29: 321-337.
28. Ryschich E, Khamidjanov A, Kerkadze V, Buchler MW, Zoller M, Schmidt J. (2009). Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer. Pancreas 38: 804-810.
29. Sagalowsky AI. (2002). The 1997 TNM classification of renal cell carcinoma revisited: the pendulum swings back. Curr Opin Urol 12: 371-373.
30. Schedl A. (2007). Renal abnormalities and their developmental origin. Nat Rev Genet 8: 791-802. (Pubitemid 47429212)
31. Shawlot W, Behringer RR. (1995). Requirement for Lim1 in head-organizer function. Nature 374: 425-430.
32. Sjolund J, Johansson M, Manna S, Norin C, Pietras A, Beckman S et al. (2008). Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 118: 217-228.
33. Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N et al. (2007). Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 67: 11668-11676.
34. Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S et al. (2006). The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66: 5130-5142. (Pubitemid 43844935)
35. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA et al. (2002). Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 61: 1714-1728. (Pubitemid 34437925)
36. Tang J, Wu YM, Zhao P, Yang XM, Jiang JL, Chen ZN. (2008). Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca2+ pathways. Cell Mol Life Sci 65: 2933-2942.
37. Venegas-Ferrin M, Sudou N, Taira M, del Pino EM. (2010). Comparison of Lim1 expression in embryos of frogs with different modes of reproduction. Int J Dev Biol 54: 195-202.
38. Yao Y, Pan Y, Chen J, Sun X, Qiu Y, Ding Y. (2007). Endoglin (CD 105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann Clin Lab Sci 37: 39-48. (Pubitemid 46350612)